PolyPid grants 9,132 stock options to director

PolyPid Ltd. director Story Brooke received a grant of 9,132 stock options to acquire Ordinary Shares at an exercise price of 4.4600 per share.

Accepted by SEC EDGAR 07/17/2026 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

PolyPid Ltd. director Story Brooke received a grant of 9,132 stock options to acquire Ordinary Shares at an exercise price of 4.4600 per share. All 9,132 options are held directly, vest on a quarterly basis beginning July 15, 2026 until April 15, 2030, and expire July 15, 2036.

Insider Trade Summary

Grant/Award: 9,132 shares

Grant/Award 1 txn

Insider Story Brooke

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy) F1	9,132	$4.46	$41K

Holdings After Transaction: Stock option (right to buy) — 9,132 contracts (Direct)

Holdings Before and After: Stock option (right to buy), 0 to 9,132 contracts (Direct)

Footnotes (1)

1. F1. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030.

Key Figures

Options Granted: 9132.0000 options Exercise Price: 4.4600 per share Shares Underlying Options: 9132.0000 Ordinary Shares +4 more

7 metrics

Options Granted 9132.0000 options Stock options granted to director Story Brooke on 2026-07-15

Exercise Price 4.4600 per share Exercise price for the granted stock options

Shares Underlying Options 9132.0000 Ordinary Shares Ordinary Shares underlying the granted stock options

Total Options After Grant 9132.0000 options Total derivative securities held directly by Story Brooke following the transaction

Vesting Start Date July 15, 2026 Options vest on a quarterly basis beginning this date

Vesting End Date April 15, 2030 Quarterly vesting continues until this date

Expiration Date July 15, 2036 Expiration date of the granted stock options

Key Terms

Stock option (right to buy), exercise price, expiration date, vest on a quarterly basis

4 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 4.4600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-07-15"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest on a quarterly basis financial

"The options vest on a quarterly basis beginning July 15, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PolyPid (PYPD) report for director Story Brooke?

PolyPid reported that director Story Brooke received a grant of 9,132 stock options to acquire Ordinary Shares at an exercise price of 4.4600 per share. These options vest quarterly from July 15, 2026 through April 15, 2030 and expire on July 15, 2036.

What is the exercise price of Story Brooke’s PolyPid (PYPD) stock options?

The options granted to Story Brooke carry an exercise price of 4.4600 per share. This means each option allows the purchase of one Ordinary Share at 4.4600, once vested and before the expiration date of July 15, 2036, subject to the vesting schedule.

When do Story Brooke’s PolyPid (PYPD) options vest?

The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030. With each quarter in this period, a portion of the 9,132 options becomes exercisable, according to the vesting schedule described in the footnote.

How many PolyPid (PYPD) options does Story Brooke hold after this grant?

Following this grant, Story Brooke holds 9,132 stock options directly, as reported in the filing’s post-transaction holdings field. These options relate to PolyPid’s Ordinary Shares and are subject to the specified quarterly vesting schedule and expiration date of July 15, 2036.

When do Story Brooke’s PolyPid (PYPD) stock options expire?

The granted options have an expiration date of July 15, 2036. Brooke may exercise vested options any time after vesting and before this date, consistent with the terms reported, including the 4.4600 per share exercise price and quarterly vesting from July 15, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Story Brooke

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET ISRAEL

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.46	07/15/2026		A		9,132		10/15/2026(1)	07/15/2036	Ordinary Shares	9,132	$4.46	9,132	D

Explanation of Responses:

1. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030.

	/s/ Story Brooke	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)